Top > News Releases
Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for YSCMA in the USA
Tokyo, Japan, and Burlingame, CA -February 13th, 2008-
Y’s Therapeutics, a privately held biopharmaceutical company, announced that the U.S.
Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct
a Phase I clinical trial for YSCMA.
YSCMA is a humanized monoclonal antibody targeted for the treatment of solid tumors and hematological cancers.
The target antigen, CD26 is a transmembrane glycoprotein found on some solid tumors such as malignant mesothelioma,
lung, prostate, liver, and ovarian cancers. The target is found to be upregulated in activated malignancies.
Multiple biological functions of the target antigen have been identified including T-cell activation, processing of
biological factors, interaction with extracellular matrix, and tumor development.
The humanized monoclonal antibody selected for further development has demonstrated antitumor activity in mouse
xenograft models with cell lines derived from T-cell Lympoma, malignant mesothelioma, etc.
A Phase I clinical trial plans to begin in USA in April 2008 and the results of the trial are expected to
be completed in March 2010.
About Y's Therapeutics
Y's Therapeutics (http://www.ysthera.com) is a privately held biopharmaceutical company engaged
in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs.
Y's focuses on the development of preclinical and early-stage clinical projects pursued through research collaborations and
in-licensing opportunities from academic institutions and biotech companies. Y's is seeking collaborative relationships,
including out-licensing of product rights and creation of joint ventures, for late-stage development,
manufacturing and commercialization of its portfolio products. The company currently has several projects
in its clinical and preclinical pipeline. Y's has operations in two locations, Y's Therapeutics Co., Ltd.,
of Tokyo, Japan, and Y's Therapeutics, Inc., of Burlingame, CA.
◈CONTACT◈
Kyoko Harigae
Administrations Department
Y's Therapeutics Co., Ltd.
E-Mail：admin@ysthera.com
 |
 |
Top | Site Map | Access Map | Privacy Policy | Terms of Use |
